1 / 17

PRESENTATION ON BRAND INDIA PROMOTION

This presentation highlights the significance of brand promotion for Indian SMEs, emphasizing better exports, margins, and positioning against China. It proposes special programs, cooperative agreements, and incentives for industry growth, emphasizing the need for shared tasks and comprehensive packages. Challenges such as lack of automation, brand development, and financial support are addressed, with suggestions for reimbursement, subsidies, and international agreements to enhance industry competitiveness and sustainability. The presentation advocates for a collaborative approach and strategic investments to propel India's pharmaceutical industry forward, ensuring global recognition and success.

tonyl
Download Presentation

PRESENTATION ON BRAND INDIA PROMOTION

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. PRESENTATION ON BRAND INDIA PROMOTION By Ashutosh Gupta COA Member -Pharmexcil Executive Director -Medicamen Biotech Ltd. Email : guptaashutosh@medicamen.com

  2. INTRODUCTION TO SME’S • Gross Capital Below 5 Crores. • 2. Top Management comprises of 2-3 individuals in most cases. • 3.Limited resources. • 4.Lack of protection and minimal chances of Bailout. • 5.Good source for employment. • 6.Lack of automation. • 7.Generic Sales / Lack of profitability.

  3. IMPORTANCE OF BRAND INDIA 1.Goes a long way to help SME’S for better exports. 2. Better acceptability of Products & Companies. 3. Better Margins. 4. Better Brand Positioning w.r.t. CHINA. 5.More investments and JV’S. 6.Big opportunity awaiting in 2012 in terms of patents expiring.

  4. BRAND INDIA PROMOTION • Special programes to upgrade the industry image abroad as well as inside the country. • Pharmacopeal leverage. • India’s own Pharma expo in India as well as abroad. • Cooperative agreements with FDA’s. • Provision of easy finance. • Incentive to SME’s for entry into regulated markets. • Task should be shared with indians abroad. • Need for comprehensive package for the industry.

  5. SPECIAL PROGRAMMES TO • UPGRADE THE INDUSTRYIMAGE • Trust building of our Government towards our Industry. • Road shows abroad. • Specific Ministerial delegations. • Special diplomatic task force. • Designated technical official in important markets in embassies.

  6. 2. PHARMACOPEAL LEVERAGE • IP is today at par with BP. • COPP’s • Brand image of Pharmacopia. • Leap jump ahead of china. • Cost effectiveness. • Better Documentation. • Better Product Range.

  7. 3. INDIA’S OWN PHARMA EXPO • Show of strength. • We will come at par with other industries. • We reach all parts of the world. • Better exposure. • International Participations.

  8. 4. COOPERATIVE AGREEMENTSwith FDA’s • Better Brand image. • Time saving. • Cost effective • Makes way for FDI’S and JV’S. • Pharmacopeal leverage. • Increase in exports.

  9. 5 PROVISION OF EASY FINANCE • SME’S always struggle due to lack of finance. • If finance is available more exports can be attained. • Easy upgradation towards CGMP/GLP. • Concentrated effort on exports. • Brand building of products. • Better image of Indian industry.

  10. 6. INCENTIVES TO SME’S FOR ENTRY INTO REGULATED MARKETS • Huge finance required. • Bioequivalence • Validations. • CTD Dossiers. • Trained regualatory staff. • Huge gestation period. • Scope of profitability. • Better number in US and EUROPE. • Jump in exports. • Better brand image. • Long lasting effects.

  11. 7.TASK SHOULD BESHARED WITH INDIANS ABROAD • Enrolment as associate members. • Most of Indians are well established . • They will feel more attatched. • Broad vision from the markets perspective. • First hand information. • Provides vast scope for improvement. • More Effective Buyer seller meet in India and abroad. • Better representation in terms of brand India. • We meet good buyers resulting in growth of exports.

  12. 8. COMPREHENSIVEPACKAGE • NEED • International conditions are very volatile. • Regulatory authorities becoming more stricter day by day. • More Documentations coming into view. • More infrastructural requirements. • Global Opportunities awaiting us. • India gaining image of Best source for low cost good quality generics.

  13. CHALLENGES TODAY • Huge Investments- Bioequivalence studies, ANDA and DMF, Validations, stability studies etc • Dying API industry. • COPP’s ( Certificate of pharmaceutical product ) • Pollution norms in API industry • Yearly updations. • Implementation of GLP • Lack of Automation • Presence in regulated markets dominated by big pharma • Lack of Brand development. • Non availablity of easy bank finance. • Lack of trained and specialised manpower • Lack of confidence of government in Pharma SME’s

  14. SUGGESTIONS • Reimbursement of bioequivalence cost atleast 50%. • Subsidised API/ ingredient units preferably PSU’s • Agreements with FDAs internationally to promote IP • Relaxation of pollution norms for the API industry • Special Incentive / subsidy for the industry on lines of tuf scheme to take care of yearly Updations • GLP upgradation subsidy shall be provided to the industry • Automation subsidy shall be provided to compete internationally. • Incentive to enter regulated markets • Marketing coops abroad should be promoted for brand development. • Banking Suggestions ( meeting with secy commerce on 13th) • More research centres like NIPER for trained manpower availaibility • Provision of a technical person in embassies

  15. OTHER SUGGESTION • Development of clusters instead of SEZs • Plant approval cost reimbursement to be included in MAI scheme • Better incentive to bulk drugs under focus market scheme • Subsidy to units for upgradation from schedule M to CGMP.

  16. LET THE VOICE BEGIN

  17. Thank You!

More Related